Diabetes Prevention

GLP-1RAs for Prediabetes Management

Diabetology & Metabolic Syndrome

Published on 2024

Summary

GLP-1RAs combined with lifestyle modifications significantly enhance prediabetes management, reverting prediabetes to normoglycemia and preventing diabetes onset.

Study Design

Interventions

LiraglutideSemaglutideLifestyle Modification

Study Type

Systematic ReviewMeta-Analysis

Outcomes

Reversion to normoglycemiaGlycemic control improvementWeight reduction

Duration and Size

medium–term_3–12_moLong-Term (1–5 y)

Large size (500–5000)

Study Population

Age Range

Middle Aged (40-64)Older Adults (65+)

Sex

MaleFemale

Geography

Global

Other Criteria

with Prediabetes

Methodology

A systematic review and meta-analysis of 12 RCTs involving 4,316 patients assessed GLP-1RAs' impact on prediabetes reversion, glycemic control, and safety profiles using standardized statistical tools and quality assessments.

Interventions

Patients received GLP-1RAs like liraglutide and semaglutide, combined with lifestyle modifications, monitored over medium and long-term durations to evaluate glycemic outcomes.

Key Findings

GLP-1RAs significantly improved glycemic parameters and reduced diabetes onset risk with a favorable safety profile, recommending them as adjunct therapy for prediabetes.

Comparison with other Studies

Compared to lifestyle interventions alone, GLP-1RAs show superior efficacy in reversing prediabetes with comparable safety outcomes reported in similar studies.

Journal Reference

Salamah H, Marey A, Abugdida M, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16:129. doi:10.1186/s13098-024-01371-3

This research summary and analysis were generated using AI-powered tools to assist in data synthesis and interpretation. While we strive for accuracy and completeness, we encourage readers to verify critical information and consult additional sources as needed. The insights presented reflect an AI-assisted perspective and should not be considered a substitute for expert opinion or independent research.

Related and Discussions

experts

GLP-1 Medicines: Where and How Do They Work?

Dr. Daniel Drucker

experts

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Prediabetes

Dr. Eric Polley

experts

GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes

Dr. Naveed Sattar

experts

TRIM—Teen Obesity and GLP-1 Receptor Agonists—Insights

Dr. Cristóbal Morales

experts

The Weight Loss Drug That Can Prevent Diabetes

Dr. Andreea Ciudin

online

Eli Lilly's Tirzepatide Shows 94% Reduction in Type 2 Diabetes Risk

Verywell Health

online

The Weight Loss Drug That Can Prevent Diabetes

Time

online

Lilly's Mounjaro Looks Unstoppable as Trial Wins Pile Up

Barron's

online

Your Love Life on Ozempic

Wired

online

Does Ozempic Help with Prediabetes?

Mayo Clinic Press

Any of you SGLT2 inhibitors and GLP1 agonists for prediabetics or ...

therationaltroll

GLP-1s like Ozempic are among the most important drug ...

FuturologyBot

Has anyone tried Exenetide or any of the GLP 1 agonists for PD?

RevolutionaryLeek320

I want to hear your nursing opinion's ozempic/GLP-1 receptor ...

Target2030

A drug approved to treat Type 2 diabetes is extremely effective at ...

AutoModerator

studies

Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: A meta-analysis

Diabetology & Metabolic Syndrome

studies

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control and weight loss in type 2 diabetes: A systematic review and network meta-analysis

The BMJ

studies

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Scientific Reports

studies

Effects of treatment with Glucagon-like peptide-1 receptor agonist on glucose metabolism, blood pressure, and body weight in prediabetes: A meta-analysis

Diabetes/Metabolism Research and Reviews

studies

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference Among Patients With Overweight or Obesity: A Systematic Review and Meta-analysis

Diabetes Care

𝕏

A GLP-1 receptor agonist (extended-release exenatide) improves smoking abstinence in smokers with prediabetes and/or overweight

Nicotine & Tobacco Research Journal

𝕏

Our May issue is now live: SGLT2 inhibitors + GLP-1 receptor agonists, light masks in diabetic retinopathy, prediabetes in the USA, & more

The Lancet Diabetes & Endocrinology

𝕏

Weight Loss–Independent Effect of Liraglutide on Metabolic Control in Prediabetes

Kevin Davy

𝕏

Meta-analysis of 11 clinical trials showing that GLP-1 receptor agonists significantly reduce the risk of kidney outcomes, major adverse cardiovascular events, and all-cause mortality

Scott Isaacs

𝕏

GLP-1 RA and Dual GIP/GLP-1RAs in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

EndoM@ne

youtube

What is a GLP-1 agonist, and how does it work?

Ohio State Medical

youtube

How GLP-1 Receptor Agonists Evolved from Diabetes to Obesity Treatments

Drug Discovery Trends

youtube

Understanding GLP-1 Medications

Harvard Medical School

youtube

Exploring GLP-1 receptor agonists with Dr Bart van der Schueren

Novo Nordisk

youtube

Expert Insights on GLP-1: Transforming Obesity & Diabetes Treatment

Medscape

Stay informed. Stay ahead.

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.